US FDA approves Novo Nordisk's Ozempic to cut risk of diabetic kidney disease progression
The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as death due to heart problems in diabetes patients with chronic kidney disease (CKD),
Stocks to Buy or Sell. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other stocks to buy and sell highlighted in Jim Cramer’s latest calls. Jim ...
Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for ...
President Donald Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals. Some, like ending birthright citizenship, are quickly slapped down in ...
Shares were mixed in thin Asian trading on Monday after U.S. stocks edged back from their all-time high. Oil prices fell and ...
VANCOUVER, BC / ACCESS Newswire / January 30, 2025 / Revolve Renewable Power Corp. ("Revolve" or the "Company"), a North American owner, operator and developer of renewable energy projects, ...
For Novo Nordisk, a company still rooted in principles ... This is particularly the case in developing nations, from Mexico to the Gulf States, China and India, where healthcare systems are ...
US stocks closed lower afer the S&P 500 touched an intraday record high early in the day. As tariff worries eased, mixed ...
It's a big week ahead as the U.S. Federal Reserve, European Central Bank and Bank of Canada hold their first meetings of 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback